These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19025451)

  • 1. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
    Saad M; Garbuzenko OB; Minko T
    Nanomedicine (Lond); 2008 Dec; 3(6):761-76. PubMed ID: 19025451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
    Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T
    Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
    Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
    Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
    Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
    J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
    Taratula O; Garbuzenko OB; Chen AM; Minko T
    J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
    Chen Y; Bathula SR; Li J; Huang L
    J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
    Misra R; Das M; Sahoo BS; Sahoo SK
    Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
    Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
    Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
    Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
    Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology.
    Xu PY; Kankala RK; Pan YJ; Yuan H; Wang SB; Chen AZ
    Int J Nanomedicine; 2018; 13():4685-4698. PubMed ID: 30154654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.
    Pakunlu RI; Cook TJ; Minko T
    Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
    Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
    Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
    Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
    Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
    Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy.
    Kang XJ; Wang HY; Peng HG; Chen BF; Zhang WY; Wu AH; Xu Q; Huang YZ
    Acta Pharmacol Sin; 2017 Jun; 38(6):885-896. PubMed ID: 28479604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.